For how we live.
A CDC field report documents the territory's largest dengue wave in over a decade, driven almost entirely by DENV-2, with one death — the first dengue-associated death there since 2005.
Surveillance data show 252 locally acquired dengue cases in the Tampa Bay area by 26 September, 223 of them in Hillsborough County, where an 80-year-old woman has died. Three counties have declared emergencies.
A single infusion of a pan-serotype monoclonal antibody cut viraemia and shortened fever in a 250-patient phase 2 trial in India — the first therapy to show preliminary efficacy against wild-type dengue in people.
Across 166,390 tests during Brazil's outbreak, two TAK-003 doses were 73% effective against symptomatic dengue and 88% against hospitalisation, with no sign of waning.
Italy logged 296 locally acquired cases in 2024, a European record. Transmission rose 19.8% per 1°C of warming, and modelling puts most of France in range for the mosquito that carries it this century.
More than 410,000 probable cases so far in 2026, against 1.45 million for all of 2025. One state, Minas Gerais, accounts for roughly a sixth of the national case total on its own.
A cluster-randomised trial in Cúcuta coated water containers in 13,803 homes. Dengue incidence fell to 337 per 100,000 versus 528 in control clusters, at about US$2 per household a year.
Two 2026 papers describe the same shift: rural incidence now exceeds urban in some years, the peak has slid to October and November, and one in six hospitalised patients progressed to severe disease.
A CDC surveillance summary puts 2024 at 359% above the 2010–2023 annual average. The 2.8% that were locally acquired are the part that changes what mosquito control has to plan for.
In a 20,000-child trial across eight endemic countries, TAK-003 was 61.2% effective against symptomatic dengue and 84.1% against hospitalisation — but protection was narrower in children never previously infected.
A cluster-randomised trial across 15 population clusters found mosquito abundance collapsed in intervention areas and protective efficacy of 71–72% against symptomatic dengue.
In a controlled human infection trial, high-dose mosnodenvir suppressed DENV-3 far below placebo. Resistance-associated changes appeared in every sequenced recipient and none of the placebo group.
The 2025 Lancet Countdown Latin America report tracks 41 indicators across 17 countries. Heat-related deaths are up 103%, and fewer than half the region's governments have finished a vulnerability assessment.